Our studies sofar has shown that inhibition of IGF-1R pathway by picropodophyllin (PPP) can be achieved with favorable therapeutic window in MM models in vivo and in vitro. Considering the acquirement of compensatory genetic lesions during MM progression it is unlikely that approaches targeting single receptors will be curative for MM. In line with this notion remaining MM cells in the in vivo 5TMM model eventually leads to relapse and mortality. To counteract this, we combined PPP in a large HTS combinatorial drug screen. In the present approach we focus on the use and molecular mechanisms of the HDAC inhibitor LBH 589 in combination with PPP in MM in vivo and in vitro.
|Effective start/end date||1/01/08 → 31/12/08|
Flemish discipline codes
- Basic sciences
- Biological sciences
- multiple myeloma